Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M) Wakelee, H., Soria, J., Camidge, R., Gadgeel, S., Goldman, J., Varga, A., Solomon, B., Papadimitrakopoulou, V., Kaur, P., Sequist, L. V. LIPPINCOTT WILLIAMS & WILKINS. 2014: S38
View details for Web of Science ID 000341688500093